High-Yield Urology
@HighYieldUro
Followers
2K
Following
80
Media
12
Statuses
229
High-Yield Urology 2025: A Guideline-Based Review Book for the In-Service, Board, and Recertification Exams • Author @BenDropkin • https://t.co/Gu10mLVnFW
Joined May 2021
🚨 @HighYieldUro 2025 Now Available! ✅ 8 new/updated guideline summaries ✅ 15 new RCTs ✅ 50 new testing pearls ✅ 15% off orders of 5+ books w/ code PROGRAM @uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology
highyieldurology.com
Urology review book focused on high-yield, testable information including urologic practice guidelines and landmark research studies.
0
5
24
🚨RC48-C016 @NEJM 🇨🇳 484 pts w/ untreated HER2(+) locally advanced or M1 UC ➡️ compared to chemo, combination Tx w/ disitamab (mAb to HER2) - vedotin & toripalimab (PD-1🛑) doubled med PFS (7 vs 13 mos) and med OS (17 vs 32 mos) & ⬇️ G3+ AE’s ✅
0
0
0
🚨 IMVigor 011 @NEJM After cystectomy for MIBC, ctDNA-guided adjuvant Atezolizumab (PD-L1 inhibitor) extended med DFS (10 vs 5 mos) and med OS (33 vs 21 mos) over placebo ✅
nejm.org
Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based detection of molecular residual disease may identify patients at high risk fo...
0
0
0
🚨LITESPARK-015 @NEJM 🌎🌍 72 patients w/ advanced, unresectable, and/or metastatic Pheochromocytoma or Paraganglioma ➡️ all got Belzutifan (HIF-2a inhibitor) ➡️ at med f/u 30 mos, obj response rate and disease control were 26% and 85% ➡️ FDA-approved ✅
nejm.org
Pheochromocytoma and paraganglioma are neoplasms originating in the adrenal medulla and extraadrenal paraganglia, respectively. Most cases of metastatic pheochromocytoma and paraganglioma are drive...
0
0
0
🔔 1️⃣ month to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ still time for a boost with @HighYieldUro 2025 📖🚀 @Uro_Res @UroResidency @urologylist @_backtableUro @ABUrology
highyieldurology.com
Urology review book focused on high-yield, testable information including urologic practice guidelines and landmark research studies.
0
4
3
🔔 1️⃣ month to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ still time for a boost with @HighYieldUro 2025 📖🚀 @Uro_Res @UroResidency @urologylist @_backtableUro @ABUrology
highyieldurology.com
Urology review book focused on high-yield, testable information including urologic practice guidelines and landmark research studies.
0
4
3
✌️ months to go!
🚨T-minus 3️⃣ months to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ great time to get ahold of @HighYieldUro 2025 📖🚀 @Uro_Res @UroResidency @urologylist @_backtableUro @ABUrology
https://t.co/fXcTUcd9FZ
0
0
2
JUST IN: Tar200 now @US_FDA approved based on SunRise-1 phase 2 trial in BCG unresponsive NMIBC. -Intravesical form of Gemcitabine - CR: 82.4%/grade ≥3 AE 12.9% - DFS 70.2% at 12m - 51% of CRs with DOR ≥ 12 months.
3
66
187
JUST IN: IMvigor011 in muscle-invasive bladder cancer (MIBC) hits both DFS & OS with PD-L1 inhibitor Atezolizumab in ctDNA+ population. Major news for Precision Oncology in adjuvant Solid Cancers! @NateraGenetics @tompowles1 @Roche
https://t.co/OlOirNfWHo
2
74
164
🚨T-minus 3️⃣ months to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ great time to get ahold of @HighYieldUro 2025 📖🚀 @Uro_Res @UroResidency @urologylist @_backtableUro @ABUrology
https://t.co/fXcTUcd9FZ
highyieldurology.com
Urology review book focused on high-yield, testable information including urologic practice guidelines and landmark research studies.
0
1
7
Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy study in the adjuvant or neoadjuvant setting with significant OS. ⬆️ pCR and EFS support this appr @OncoAlert @Annals_Oncology
https://t.co/EfftVBphaF
0
62
164
I wish I had @HighYieldUro at the start of my residency @brady_urology. It is a great preparation tool for grand rounds and didactics. By adding your own notes in the margins you can tailor it for your own rapid review before In-Service and Boards.
highyieldurology.com
Urology review book focused on high-yield, testable information including urologic practice guidelines and landmark research studies.
1
3
15
JUST IN: @US_FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer! Approval based on ENVISION NCT05243550 trial ! @DanaFarber_GU @AmerUrological
4
25
72
📢 Big win for a rare kidney cancer subtype! In HLRCC-associated papillary RCC, bevacizumab + erlotinib delivered a 72% response rate and median PFS of 21.1 months. 🧬 Germline FH-mutated pRCC finally gets a targeted shot. #Oncology #RCC #HLRCC #KidneyCancer #PrecisionMedicine
0
42
115
And then there was ☝️month until @ABUrology Part I Boards!
🚨 @HighYieldUro 2025 Now Available! ✅ 8 new/updated guideline summaries ✅ 15 new RCTs ✅ 50 new testing pearls ✅ 15% off orders of 5+ books w/ code PROGRAM @uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology
0
0
1
⏳T-minus 2️⃣ months until @ABUrology Part I Boards ➡️ great time to grab the fully updated 2025 edition of @HighYieldUro 🚀
highyieldurology.com
Urology review book focused on high-yield, testable information including urologic practice guidelines and landmark research studies.
0
0
6
Congratulations to all the newly @ABUrology Board Certified urologists! An enormous achievement many years in the making 👏🍾
0
2
9
⏳T-minus 3️⃣ months until @ABUrology Part I Boards ➡️ great time to start your exam prep with the fully updated 2025 edition of @HighYieldUro 🚀
🚨 @HighYieldUro 2025 Now Available! ✅ 8 new/updated guideline summaries ✅ 15 new RCTs ✅ 50 new testing pearls ✅ 15% off orders of 5+ books w/ code PROGRAM @uro_res @uroresidency @urologylist @_backtableuro @AmerUrological @ABUrology
0
0
2
🚨BARCODE1 @NEJM 🇬🇧 population-based prostate cancer screening using top decile of saliva-based DNA “Polygenic Risk Score” as indication for further evaluation with MRI + biopsy
nejm.org
The incidence of prostate cancer is increasing. Screening with an assay of prostate-specific antigen (PSA) has a high rate for false positive results. Genomewide association studies have identified...
0
0
2
🚨 AUA/SUFU Guideline Update: Microhematuria 👉 refined risk stratification, diagnosis, and surveillance recommendations 👏 @DanBarocas & Team @AmerUrological @sufuorg @ABUrology
auajournals.org
Purpose:Patients presenting with microhematuria represent a heterogeneous population with a broad spectrum of risk for genitourinary malignancy. Recognizing that patient-specific characteristics...
0
7
16